bone diseases

Summary

Summary: Diseases of BONES.

Articles from Journal RESEARCH

Top Publications

  1. ncbi Therapeutic approaches to bone diseases
    G A Rodan
    Merck Research Laboratories, West Point, PA 19486, USA St Vincent s Institute of Medical Research, Melbourne 3065, Australia
    Science 289:1508-14. 2000
  2. ncbi Receptor activator of nuclear factor-kappaB ligand and osteoprotegerin: potential implications for the pathogenesis and treatment of malignant bone diseases
    L C Hofbauer
    Division of Gastroenterology, Endocrinology and Metabolism, Department of Medicine, Philipps University, Baldingerstrasse, D 35033 Marburg, Germany
    Cancer 92:460-70. 2001
  3. ncbi Stem cells in bone diseases: current clinical practice
    Shaul Beyth
    Orthopedic Surgery Department, Hadassah Hebrew University Medical Center, Ein Kerem, POB 12000, Jerusalem 91120, Israel
    Br Med Bull 99:199-210. 2011
  4. ncbi Factors associated with low bone mineral density in a Brazilian cohort of vertically HIV-infected adolescents
    Annie Schtscherbyna
    Department of Endocrinology, Hospital Universitario Clementino Fraga Filho, Universidade Federal do Rio de Janeiro, Alegre, 289 203 Jardim Guanabara, Rio de Janeiro, 21931 260 Brazil
    Int J Infect Dis 16:e872-8. 2012
  5. ncbi Subchondral bone and cartilage disease: a rediscovered functional unit
    H Imhof
    Osteologie, Univ Klinik fur Radiodiagnostik, AKH Vienna, Austria
    Invest Radiol 35:581-8. 2000
  6. pmc Cadmium osteotoxicity in experimental animals: mechanisms and relationship to human exposures
    Maryka H Bhattacharyya
    Environmental Sciences Division, Argonne National Laboratory, Lemont, IL 60439, USA
    Toxicol Appl Pharmacol 238:258-65. 2009
  7. pmc Improvement of bone disease by imiglucerase (Cerezyme) therapy in patients with skeletal manifestations of type 1 Gaucher disease: results of a 48-month longitudinal cohort study
    K B Sims
    Department of Neurology, Massachusetts General Hospital, Boston, MA 02114, USA
    Clin Genet 73:430-40. 2008
  8. ncbi Clinical utility of (18)F-fluoride PET/CT in benign and malignant bone diseases
    Yuxin Li
    VA Greater Los Angeles Healthcare System, Los Angeles, CA 90073, USA
    Bone 50:128-39. 2012
  9. ncbi Bisphosphonate-decorated lipid nanoparticles designed as drug carriers for bone diseases
    Guilin Wang
    Department of Chemical and Materials Engineering, Faculty of Engineering, University of Alberta, Edmonton, Alberta, Canada
    J Biomed Mater Res A 100:684-93. 2012
  10. ncbi Involvement of ICAM-1 in bone metabolism: a potential target in the treatment of bone diseases?
    Patrick Lavigne
    Hopital du Sacre Coeur de Montreal, Orthopedics Research Laboratory, Department of Orthopedics, 5400 Boul Gouin Ouest, Montreal, Quebec, H4J 1C5, Canada
    Expert Opin Biol Ther 5:313-20. 2005

Detail Information

Articles from Journal RESEARCH1

Publications246 found, 100 shown here

  1. ncbi Therapeutic approaches to bone diseases
    G A Rodan
    Merck Research Laboratories, West Point, PA 19486, USA St Vincent s Institute of Medical Research, Melbourne 3065, Australia
    Science 289:1508-14. 2000
    ..Far less attention has been paid to promoting bone formation with, for example, growth factors or hormones, an approach that would be a valuable adjunct therapy for patients receiving inhibitors of bone resorption...
  2. ncbi Receptor activator of nuclear factor-kappaB ligand and osteoprotegerin: potential implications for the pathogenesis and treatment of malignant bone diseases
    L C Hofbauer
    Division of Gastroenterology, Endocrinology and Metabolism, Department of Medicine, Philipps University, Baldingerstrasse, D 35033 Marburg, Germany
    Cancer 92:460-70. 2001
    ..Furthermore, it highlights the impact of these compounds on the pathogenesis of malignant bone diseases, including tumor metastasis, humoral hypercalcemia of malignancy, and multiple myeloma...
  3. ncbi Stem cells in bone diseases: current clinical practice
    Shaul Beyth
    Orthopedic Surgery Department, Hadassah Hebrew University Medical Center, Ein Kerem, POB 12000, Jerusalem 91120, Israel
    Br Med Bull 99:199-210. 2011
    ..Bone is an obvious candidate tissue for stem cell therapy. This review provides an update of existing stem cell-based clinical treatments for bone pathologies...
  4. ncbi Factors associated with low bone mineral density in a Brazilian cohort of vertically HIV-infected adolescents
    Annie Schtscherbyna
    Department of Endocrinology, Hospital Universitario Clementino Fraga Filho, Universidade Federal do Rio de Janeiro, Alegre, 289 203 Jardim Guanabara, Rio de Janeiro, 21931 260 Brazil
    Int J Infect Dis 16:e872-8. 2012
    ..To assess the prevalence and factors associated with low bone mineral density (BMD) in HIV-infected adolescents...
  5. ncbi Subchondral bone and cartilage disease: a rediscovered functional unit
    H Imhof
    Osteologie, Univ Klinik fur Radiodiagnostik, AKH Vienna, Austria
    Invest Radiol 35:581-8. 2000
    ....
  6. pmc Cadmium osteotoxicity in experimental animals: mechanisms and relationship to human exposures
    Maryka H Bhattacharyya
    Environmental Sciences Division, Argonne National Laboratory, Lemont, IL 60439, USA
    Toxicol Appl Pharmacol 238:258-65. 2009
    ..Identifying environmental factors such as cadmium that contribute to increased fractures in humans is an important undertaking and a first step to prevention...
  7. pmc Improvement of bone disease by imiglucerase (Cerezyme) therapy in patients with skeletal manifestations of type 1 Gaucher disease: results of a 48-month longitudinal cohort study
    K B Sims
    Department of Neurology, Massachusetts General Hospital, Boston, MA 02114, USA
    Clin Genet 73:430-40. 2008
    ..17 +/- 1.206 (p = 0.035) at month 36. This increase was sustained at 48 months. With imiglucerase treatment, patients should anticipate resolution of BC, rapid improvement in BP, increases in BMD, and decreased skeletal complications...
  8. ncbi Clinical utility of (18)F-fluoride PET/CT in benign and malignant bone diseases
    Yuxin Li
    VA Greater Los Angeles Healthcare System, Los Angeles, CA 90073, USA
    Bone 50:128-39. 2012
    ..the expanding clinical usage of PET/CT, there is renewed interest in using (18)F-fluoride PET/CT for imaging bone diseases. Growing evidence indicates that (18)F fluoride PET/CT offers increased sensitivity, specificity, and ..
  9. ncbi Bisphosphonate-decorated lipid nanoparticles designed as drug carriers for bone diseases
    Guilin Wang
    Department of Chemical and Materials Engineering, Faculty of Engineering, University of Alberta, Edmonton, Alberta, Canada
    J Biomed Mater Res A 100:684-93. 2012
    ..The designed liposomes were able to entrap the bone morphogenetic protein-2 in a bioactive form, indicating that the proposed nanocarriers could deliver bioactive factors locally in mineralized scaffolds for bone tissue engineering...
  10. ncbi Involvement of ICAM-1 in bone metabolism: a potential target in the treatment of bone diseases?
    Patrick Lavigne
    Hopital du Sacre Coeur de Montreal, Orthopedics Research Laboratory, Department of Orthopedics, 5400 Boul Gouin Ouest, Montreal, Quebec, H4J 1C5, Canada
    Expert Opin Biol Ther 5:313-20. 2005
    b>Bone diseases such as osteoporosis, osteoarthritis and rheumatoid arthritis (RA) affect a great proportion of individuals, with debilitating consequences in terms of pain and progressive limitation of function...
  11. ncbi The challenge of establishing preclinical models for segmental bone defect research
    Johannes C Reichert
    Institute of Health and Biomedical Innovation, Queensland University of Technology, Brisbane, 60 Musk Avenue, Kelvin Grove, QLD 4059, Australia
    Biomaterials 30:2149-63. 2009
    ....
  12. ncbi Novel therapies in benign and malignant bone diseases
    Tilman D Rachner
    Division of Endocrinology, Diabetes, and Bone Diseases TDR, LCH, Technical University, Dresden, Germany
    Pharmacol Ther 134:338-44. 2012
    With an ageing population and improving cancer therapies, the two most common benign and malignant bone diseases, osteoporosis and bone metastases, will continue to affect an increasing number of patients...
  13. ncbi Bone mineralization density distribution in health and disease
    P Roschger
    4th Medical Department, Hanusch Hospital, Heinrich Collin Street 30, A 1140, Vienna, Austria
    Bone 42:456-66. 2008
    ..the BMDD in bone biopsies led to numerous applications of BMDD in the evaluation of diagnosis and treatment of bone diseases, while advancing the understanding of the bone material, concomitantly...
  14. ncbi Pattern and course of single-system disease in Langerhans cell histiocytosis data from the DAL-HX 83- and 90-study
    C Titgemeyer
    St. Anna Children's Hospital, Kinderspitalgasse 6, A-1090 Vienna, Austria
    Med Pediatr Oncol 37:108-14. 2001
    ..However, reactivations had an impact on morbidity, as permanent consequences were mostly related to the site of disease activity. Med Pediatr Oncol 2001;37:108-114...
  15. ncbi Skeletal bone diseases impact the periodontium: a review of bisphosphonate therapy
    Leena Palomo
    Case Western Reserve University, Department of Periodontics, School of Dental Medicine, 10900 Euclid Ave, Cleveland OH, 44106 4905, USA
    Expert Opin Pharmacother 8:309-15. 2007
    ..Developing bisphosphonates to slow the progression of periodontal disease depends on identifying an effective dosage regimen and delivery system that would reach the target site in the periodontium, while limiting unwanted side effects...
  16. ncbi Adult langerhans cell histiocytosis of bones : a rare cancer network study
    Banu Atalar
    Rare Cancer Network RCN
    Acta Orthop Belg 76:663-8. 2010
    ..003). Surgery plays a major role in the treatment of adult LCH of bones ; radiotherapy should be considered in the adjuvant setting and palliation...
  17. ncbi Long-term efficacy and safety of zoledronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma: a randomized, double-blind, multicenter, comparative trial
    Lee S Rosen
    Developmental Therapeutics, Cancer Institute Medical Group, Santa Monica, California 90095, USA
    Cancer 98:1735-44. 2003
    ..The goal of the current study was to compare the long-term (25-month) safety and efficacy of zoledronic acid with pamidronate in patients with bone lesions secondary to advanced breast carcinoma or multiple myeloma...
  18. pmc Wnt signaling as a therapeutic target for bone diseases
    Luke H Hoeppner
    Graduate Program in Microbiology, Immunology and Cancer Biology, University of Minnesota, Minneapolis, MN, USA
    Expert Opin Ther Targets 13:485-96. 2009
    ..There is a need to develop new bone anabolic agents because current bone regeneration regimens have limitations. The Wingless-type MMTV integration site (Wnt) pathway has emerged as a regulator of bone formation and regeneration...
  19. ncbi Wnt signaling in osteoblasts and bone diseases
    Jennifer J Westendorf
    The Cancer Center and Department of Orthopaedic Surgery, University of Minnesota, MMC 806, 420 Delaware St SE, Minneapolis, MN 55455, USA
    Gene 341:19-39. 2004
    ..We also discuss regulatory mechanisms discovered in developmental and tumor models that may provide insights into novel therapies for bone diseases.
  20. ncbi Impact of the Kidney Disease Outcomes Quality Initiative (KDOQI) Clinical Practice Guidelines for Bone Metabolism and Disease in a large dialysis network
    Ron Wald
    Department of Medicine, Division of Nephrology, St Michael s Hospital and University of Toronto, Ontario, Canada
    Am J Kidney Dis 49:257-66. 2007
    ..The impact of the Kidney Disease Outcomes Quality Initiative (KDOQI) Clinical Practice Guidelines for Bone Metabolism and Disease in Chronic Kidney Disease has not been assessed...
  21. ncbi Skeletal aspects of Gaucher disease: a review
    R J Wenstrup
    Division and Program in Human Genetics, Children s Foundation Research Hospital, Cincinnati, Ohio 45229, USA
    Br J Radiol 75:A2-12. 2002
    ....
  22. pmc Nanotechnology in the targeted drug delivery for bone diseases and bone regeneration
    Wenyi Gu
    Institute of Health and Biomedical Innovation, Queensland University of Technology, Brisbane, QLD, Australia
    Int J Nanomedicine 8:2305-17. 2013
    ..Similarly, this technique has been used for treating bone diseases including bone regeneration...
  23. ncbi Pelvic bone hydatidosis
    F Gdoura
    Service de Chirurgie Orthopedique et Traumatologique, Faculte de Medecine de Sfax, CHU Habib Bourguiba, route El Ain Km 0, 5 CP, 3029 Sfax, Tunisie
    Orthop Traumatol Surg Res 96:85-9. 2010
    ..Pelvic locations are particularly difficult to treat. After an enlarged and difficult surgical resection, reconstruction remains aleatory and poses many technical problems...
  24. ncbi Targeting the Wnt/beta-catenin pathway to regulate bone formation in the adult skeleton
    Roland Baron
    Yale University School of Medicine, 333 Cedar Street, P O Box 208044, New Haven, CT 06520 8044, USA
    Endocrinology 148:2635-43. 2007
    ..Multiple genetic and pharmacological manipulations of Wnt signaling in mice have since then confirmed the central role of this pathway in regulating bone formation...
  25. ncbi Ossicles associated with chronic pain around the malleoli of the ankle
    S H Han
    Department of Orthopaedic Surgery, Ajou University School of Medicine, Wonchon dong, Yeongtong Gu, Suwon 443 721, South Korea
    J Bone Joint Surg Br 90:1049-54. 2008
    ..5 to 93 points (p < 0.001). Overall, the rate of patient satisfaction was 88%. Our results indicate that symptomatic ossicles of the malleoli respond well to arthroscopic treatment...
  26. ncbi The distinct role of the Runx proteins in chondrocyte differentiation and intervertebral disc degeneration: findings in murine models and in human disease
    Shingo Sato
    Tokyo Medical and Dental University, Tokyo, Japan
    Arthritis Rheum 58:2764-75. 2008
    ....
  27. ncbi Cell biology of osteoimmunology
    Reinhard Gruber
    Department of Oral Surgery, Medical University of Vienna, Vienna, Austria
    Wien Med Wochenschr 160:438-45. 2010
    ..Our current understanding has already provided the scientific basis for the development of targeted therapies. However, the challenge of future studies is to further decipher this crosstalk at cellular and molecular levels...
  28. ncbi Age-related alterations in mesenchymal stem cells related to shift in differentiation from osteogenic to adipogenic potential: implication to age-associated bone diseases and defects
    MiJung Kim
    Department of Genetics, Albert Einstein College of Medicine, 1301 Morris Park Avenue, Bronx, NY 10461, USA
    Mech Ageing Dev 133:215-25. 2012
    ..described here including transcription factors, microRNAs and FoxOs could be used towards development of treatment regimens for age-related bone diseases and related defects based on mutually exclusive lineage fate determination of MSC.
  29. ncbi The conclusiveness of less-invasive imaging techniques (computer tomography, X-ray) with regard to their identification of bone diseases in a primate model (Callithrix jacchus)
    J Grohmann
    Institute of Physiological Chemistry, University of Leipzig, Leipzig, Germany
    J Med Primatol 41:130-7. 2012
    Although common marmosets seem to be appropriate animal models to examine bone diseases, no data about the conclusiveness of less-invasive techniques are available...
  30. ncbi FGF23 associated bone diseases
    Eryuan Liao
    Institute of Metabolism and Endocrinology, The Second Xiangya Hospital, Central South University, Changsha, 410011, China
    Front Med 7:65-80. 2013
    ..In this review, we summarized the FGF superfamily, the mechanism of FGF23 on phosphate and vitamin D metabolism, and the FGF23 related bone disease...
  31. ncbi Impact of lanthanum carbonate on cortical bone in dialysis patients with adynamic bone disease
    Aiji Yajima
    Department of Pathology, The University of Texas, Southwestern Medical Center, Dallas, TX, USA
    Ther Apher Dial 17:41-8. 2013
    ....
  32. ncbi Leptin in joint and bone diseases: new insights
    M Scotece
    SERGAS, Research Laboratory 9, Institute of Medical Research, Santiago University Clinical Hospital, Santiago de Compostela, 15706, Spain
    Curr Med Chem 20:3416-25. 2013
    ....
  33. ncbi Challenging the current approaches to multiple myeloma- and other cancer-related bone diseases: from bisphosphonates to targeted therapy
    Martina Kleber
    Department of Hematology and Oncology, University Medical Center Freiburg, Freiburg, Germany
    Leuk Lymphoma 53:1057-61. 2012
    ..myeloma meeting entitled "Challenging the current approaches to multiple myeloma- and other cancer-related bone diseases: from bisphosphonates to targeted therapy" was held in Freiburg, Germany in July 2011 to discuss novel ..
  34. ncbi Evidence-based recommendations for monitoring bone disease and the response to enzyme replacement therapy in Gaucher patients
    Stephan vom Dahl
    Department of Internal Medicine, St Franziskus Hospital, Cologne, Germany
    Curr Med Res Opin 22:1045-64. 2006
    ..Enzyme replacement therapy reverses many of the clinical signs of Gaucher bone disease but early assessment and treatment, and regular monitoring, are essential in optimising outcomes...
  35. ncbi Painful accessory bones of the foot
    Theodore T Miller
    Department of Radiology, North Shore University Hospital, Manhasset, NY, USA
    Semin Musculoskelet Radiol 6:153-61. 2002
    ..Occasionally these ossicles can become painful due to fracture, degenerative changes, avascular necrosis, and irritation or impingement of adjacent soft tissue...
  36. ncbi Treatment strategies for bone disease
    G D Roodman
    Department of Medicine Hematology Oncology, VA Pittsburgh Healthcare System, University of Pittsburgh, Pittsburgh, PA 15240, USA
    Bone Marrow Transplant 40:1139-46. 2007
    ..New therapies that can target both the tumor as well as the severe bone disease should be on the horizon to treat this devastating complication of myeloma...
  37. pmc A single amino acid substitution (D1441Y) in the carboxyl-terminal propeptide of the proalpha1(I) chain of type I collagen results in a lethal variant of osteogenesis imperfecta with features of dense bone diseases
    J M Pace
    Department of Pathology, University of Washington, Seattle, WA, USA
    J Med Genet 39:23-9. 2002
    ..trabeculae with retained cartilage in long bones, and diminished marrow spaces similar to those seen in dense bone diseases such as osteopetrosis and pycnodysostosis...
  38. ncbi Preformed grafts of porcine small intestine submucosa (SIS) for bridging segmental bone defects
    Douglas C Moore
    The Orthopaedic Research Laboratories, Department of Orthopaedics, Brown Medical School Rhode Island Hospital, CORO West, Suite 404, 1 Hoppin Street, Providence, RI 02903, USA
    J Biomed Mater Res A 69:259-66. 2004
    ..Additional work will be required to determine whether our results reflect the protocols used to prepare and fabricate the SIS grafts used in the study or the inherent inability of SIS to support new bone growth...
  39. ncbi Treatment of bone diseases with bisphosphonates, excluding osteoporosis
    J P Devogelaer
    Department of Rheumatology, St Luc University Hospital, Universite Catholique de Louvain, Brussels, Belgium
    Curr Opin Rheumatol 12:331-5. 2000
    ..Now that the fear of theoretically freezing bone remodeling has been reasonably dismissed, potential uses for bisphosphonates might be considered nearly infinite...
  40. pmc The ephrinB2/EphB4 axis is dysregulated in osteoprogenitors from myeloma patients and its activation affects myeloma bone disease and tumor growth
    Angela Pennisi
    Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, AR 72205, USA
    Blood 114:1803-12. 2009
    ..Myeloma cells expressed low to undetectable ephrinB2 and EphB4 and did not respond to the chimeric proteins. The ephrinB2/EphB4 axis is dysregulated in MM, and its activation by EphB4-Fc inhibits myeloma growth and bone disease...
  41. ncbi Biphasic anti-osteoclastic action of intravenous alendronate therapy in multiple myeloma bone disease
    Masayasu Kitano
    Division of Clinical Immunology, Department of Internal Medicine, Hyogo College of Medicine, 1 1 Mukogawa cho, Nishinomiya 663 8131, Japan
    J Bone Miner Metab 23:48-52. 2005
    ..Our results suggest that impaired activity of monocytes, which are possible osteoclast precursors, is related to reduced bone destruction in multiple myeloma...
  42. ncbi Treatment of Langerhans cell histiocytosis bone lesions with zoledronic acid: a case series
    Shanthi Sivendran
    Penn State Milton S Hershey Medical Center, The Department of Medicine, Division of Hematology Oncology, H046, 500 University Drive, PO Box 850, Hershey, PA 17033 0850, USA
    Int J Hematol 93:782-6. 2011
    ..This case demonstrates the potential role of zoledronic acid therapy in the first line setting for disease stabilization and symptomatic control in patients unable to receive conventional therapy...
  43. ncbi Historical perspectives on the clinical development of bisphosphonates in the treatment of bone diseases
    M D Francis
    Procter and Gamble Pharmaceuticals, Mason, OH, USA
    J Musculoskelet Neuronal Interact 7:2-8. 2007
    ..The end result of these efforts has provided health care professionals with diagnostic and therapeutic tools to improve the lives of patients...
  44. ncbi Evaluation of implant osseointegration with different regeneration techniques in the treatment of bone defects around implants: an experimental study in a rabbit model
    Isabel Guerra
    Clin Oral Implants Res 22:314-22. 2011
    ..The aim of this study was to evaluate the osseointegration of implants placed in areas with artificially created bone defects, using three bone regeneration techniques...
  45. ncbi Vitamin D nutrition and bone disease in adults
    E B Mawer
    University Department of Medicine, Manchester Royal Infirmary, Oxford Road, Manchester M13 9WL, UK
    Rev Endocr Metab Disord 2:153-64. 2001
    ....
  46. pmc Structural and functional characterization of recombinant matrilin-3 A-domain and implications for human genetic bone diseases
    Maryline Fresquet
    Wellcome Trust Centre for Cell Matrix Research, Faculty of Life Sciences, University of Manchester, Michael Smith Building, Oxford Road, Manchester M13 9PT, United Kingdom
    J Biol Chem 282:34634-43. 2007
    ..Furthermore, we have also determined that the matrilin-3 A-domain appears to bind exclusively to the COL3 domain of type IX collagen and that this binding is abolished in the presence of a disease causing mutation in type IX collagen...
  47. ncbi Allogeneic mesenchymal stem cells regenerate bone in a critical-sized canine segmental defect
    Treena Livingston Arinzeh
    Osiris Therapeutics, Baltimore, Maryland, USA
    J Bone Joint Surg Am 85:1927-35. 2003
    ..The objective of this study was to determine whether the use of allogeneic mesenchymal stem cells could heal a critical-sized bone defect in the femoral diaphysis in dogs without the use of immunosuppressive therapy...
  48. ncbi Imiglucerase (Cerezyme) improves quality of life in patients with skeletal manifestations of Gaucher disease
    N Weinreb
    University Research Foundation for Lysosomal Storage Diseases, Coral Springs, FL 33065, USA
    Clin Genet 71:576-88. 2007
    ..Imiglucerase treatment has a significant positive impact on HRQOL of type 1 GD patients with skeletal disease, including those with bone infarctions, lytic lesions, and avascular necrosis...
  49. ncbi Mesenchymal cells for skeletal tissue engineering
    N J Panetta
    Department of Surgery, Stanford University School of Medicine, Stanford, CA 94305 148, USA
    Panminerva Med 51:25-41. 2009
    ....
  50. pmc Mesenchymal stem cells for bone repair and metabolic bone diseases
    Anita H Undale
    Endocrine Research Unit, Mayo Clinic, Rochester, MN 55905, USA
    Mayo Clin Proc 84:893-902. 2009
    ..Patients who experience fracture nonunion and metabolic bone diseases, such as osteogenesis imperfecta and hypophosphatasia, have benefited from human mesenchymal stem cell therapy...
  51. ncbi RANKL-RANK signaling in osteoclastogenesis and bone disease
    Teiji Wada
    Institute of Molecular Biotechnology of the Austrian Academy of Sciences IMBA, Dr Bohrgasse 3, A 1030 Vienna, Austria
    Trends Mol Med 12:17-25. 2006
    ..of osteoclast development and osteoclast function were significant turning points in our understanding of bone diseases. RANKL-RANK signaling activates a variety of downstream signaling pathways required for osteoclast development...
  52. ncbi High prevalence of vitamin D inadequacy and implications for health
    Michael F Holick
    Vitamin D, Skin and Bone Research Laboratory, Section of Endocrinology, Diabetes, and Nutrition, Department of Medicine, Boston University School of Medicine, Boston, Mass 02118, USA
    Mayo Clin Proc 81:353-73. 2006
    ..The purposes of this article are to examine the prevalence of vitamin D inadequacy and to review the potential implications for skeletal and extraskeletal health...
  53. ncbi Guide to bone health and disease in cystic fibrosis
    Robert M Aris
    CB 7020, 4131 Bioinformatics, University of North Carolina, Chapel Hill, North Carolina 27599 7524, USA
    J Clin Endocrinol Metab 90:1888-96. 2005
    ..The goal of this conference was to develop practice guidelines for optimizing bone health in patients with CF...
  54. ncbi Reconstruction of large cranial defects in nonimmunosuppressed experimental design with human dental pulp stem cells
    André de Mendonça Costa
    Departamento de Cirurgia Plástica e Queimaduras, Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo, Brazil
    J Craniofac Surg 19:204-10. 2008
    ..Our findings suggest that hDPSC is an additional cell resource for correcting large cranial defects in rats and constitutes a promising model for reconstruction of human large cranial defects in craniofacial surgery...
  55. ncbi Use of daptomycin to treat drug-resistant Gram-positive bone and joint infections
    Michael S Finney
    Fountain Valley Regional Hospital, Fountain Valley, CA, USA
    Curr Med Res Opin 21:1923-6. 2005
    ..This report describes the experience in a series of cases of the use of a novel antibiotic, daptomycin, for the treatment of bone and joint infections...
  56. ncbi Imaging of osteomyelitis: current concepts
    Carlos Pineda
    Instituto Nacional de Rehabilitacion, Avenida México Xochimilco No 289, Arenal de Guadalupe, Tlalpan, Mexico City, 14389, Mexico
    Infect Dis Clin North Am 20:789-825. 2006
    ..PET and SPECT are highly accurate techniques for the evaluation of chronic osteomyelitis, allowing differentiation from soft tissue infection...
  57. ncbi Superior effects of high-dose enzyme replacement therapy in type 1 Gaucher disease on bone marrow involvement and chitotriosidase levels: a 2-center retrospective analysis
    Maaike de Fost
    Department of Internal Medicine, Endocrinology and Metabolism, F4 279, University of Amsterdam, Academic Medical Center, 1100 DD Amsterdam, The Netherlands
    Blood 108:830-5. 2006
    ....
  58. ncbi Role of RANKL in bone diseases
    Allen P Anandarajah
    Division of Allergy, University of Rochester Medical Center, Rochester, NY 14642, USA
    Trends Endocrinol Metab 20:88-94. 2009
    ..Here, I provide an overview of recent studies that highlight the key role of RANKL in the pathophysiology of several bone diseases and discuss the novel therapeutic approaches afforded by the modulation of RANKL.
  59. ncbi Novel bone-targeted strategies in oncology
    Sonia Vallet
    Department of Medicine, Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA, USA
    Clin Cancer Res 16:4084-93. 2010
    ....
  60. ncbi Single-photon emission computed tomography combined with computed tomography (SPECT/CT) in bone diseases
    Dimitri Papathanassiou
    Service de Medecine Nucleaire, Institut Jean Godinot, 51056 Reims Cedex, France
    Joint Bone Spine 76:474-80. 2009
    ..However, SPECT/CT is only starting to become available and may become a routine investigation for a number of rheumatic disorders...
  61. ncbi Hydatid cyst of bone: diagnosis and treatment
    M Zlitni
    Orthopedic Surgery Department, Charles Nicolle Hospital, Tunis, Tunisia
    World J Surg 25:75-82. 2001
    ..The prognosis and treatment of osseous hydatidosis belong in the same category as a locally malignant lesion...
  62. ncbi Langerhans' cell histiocytosis: pathology, imaging and treatment of skeletal involvement
    E Michel Azouz
    Pediatric Radiology Section, Department of Radiology, University of Miami, R 109, P O Box 016960, Miami, FL 33101, USA
    Pediatr Radiol 35:103-15. 2005
    ..CT is better suited for demonstrating bone detail and MR imaging for bone marrow and soft-tissue involvement...
  63. ncbi Tissue engineering of bone: the reconstructive surgeon's point of view
    U Kneser
    Department of Plastic and Hand Surgery, University of Erlangen Medical Center, Krankenhausstrasse 12, 91054 Erlangen Germany
    J Cell Mol Med 10:7-19. 2006
    ..Concepts for the induction of axial vascularization in engineered bone tissues as well as potential clinical applications are discussed in detail...
  64. ncbi Nosology and classification of genetic skeletal disorders: 2006 revision
    Andrea Superti-Furga
    Center for Pediatrics and Adolescent Medicine, Department of Pediatrics, University of Freiburg, Freiburg, Germany
    Am J Med Genet A 143:1-18. 2007
    ....
  65. ncbi Extraspinal bone hydatidosis
    Antonio Herrera
    Department of Orthopaedic and Trauma Surgery, Miguel Servet University Hospital, Zaragoza, Spain
    J Bone Joint Surg Am 85:1790-4. 2003
    ..Bone hydatidosis caused by the tapeworm larva, Echinococcus granulosis, is rare. Extraspinal locations are even rarer. We report our experience with the treatment of twenty-six patients with extraspinal osseous hydatidosis...
  66. ncbi A case of pelvic bone hydatidosis--diagnosis and treatment
    Vladimir P Stavrev
    Department of Orthopedics and Traumatology, University Hospital St George, Medical University, Plovdiv, Bulgaria
    Folia Med (Plovdiv) 48:60-3. 2006
    ..Echinococcosis is a frequent helminthiasis in Bulgaria. Hydatid cysts commonly affect the liver and the lung. Echinococcosis rarely involves bones (0.5 to 2.5%) and vertebral column is affected in 50% of the cases...
  67. ncbi Myeloma bone disease and treatment options
    Howard S Yeh
    Hematology Oncology Department, Institute for Myeloma and Bone Cancer Research, 9201W Sunset Blvd, Suite 300, W Hollywood, CA 90069, USA
    Eur J Cancer 42:1554-63. 2006
    ..As our understanding of the pathophysiology of myeloma bone disease continues to increase, new target therapies will continue to emerge offering new and more advanced options for the management of myeloma bone disease...
  68. ncbi Influence of RANKL inhibition on immune system in the treatment of bone diseases
    Anne Fouque-Aubert
    Service de Rhumatologie, Hopital Edouard Herriot, 5 Place d Arsonval, 69437 Lyon Cedex, France
    Joint Bone Spine 75:5-10. 2008
    ..So, blocking RANKL could interplay with immune cells and have systemic effects. Here, we review biological data regarding potential consequences of RANKL blocking on the immune system...
  69. ncbi Nanotechnology controlled drug delivery for treating bone diseases
    Lei Yang
    Brown University, Division of Engineering, Providence, RI 02912, USA
    Expert Opin Drug Deliv 6:851-64. 2009
    ..of nanotechnology and controlled drug delivery have triggered exceptional growth in treating various bone diseases. As a result, over the past decade, nanotechnology has contributed tremendously to controlling drug delivery ..
  70. ncbi Long bone reconstruction with vascularized bone grafts
    William C Pederson
    The Hand Center of San Antonio, and Department of Orthopaedic Surgery, The University of Texas Health Science Center at San Antonio, San Antonio, TX 78240, USA
    Orthop Clin North Am 38:23-35, v. 2007
    ..The vascularized fibula can be used to maintain growth by virtue of transferring the physis. The vascularized fibula is thus both the workhorse and thoroughbred in long bone construction...
  71. ncbi The pathophysiological role of PEDF in bone diseases
    M L Broadhead
    Department of Orthopaedics and University of Melbourne Department of Surgery, St Vincent s Hospital, Vic, Australia
    Curr Mol Med 10:296-301. 2010
    ..Surprisingly, the role of PEDF has not been evaluated more widely in bone disorders, so the challenge ahead lies in a more diverse evaluation of PEDF in various osteologic pathologies including osteoarthritis and fracture healing...
  72. ncbi Extensive hydatidosis of the femur and pelvis with pathological fracture: a case report
    Ramchander Siwach
    Department of Orthopaedic Surgery, Paraplegia and Rehabilitation, Pt B D Sharma PGIMS, Rohtak 124001, Haryana, India
    Int J Infect Dis 13:e480-2. 2009
    ..Hydatid cysts caused by Echinococcus sp can produce tissue cysts anywhere in the body. Skeletal cystic lesions are rare, yet because of their unusual presentation diagnosis can be missed...
  73. ncbi The effect of enzyme replacement therapy on bone crisis and bone pain in patients with type 1 Gaucher disease
    J Charrow
    Department of Pediatrics, Feinberg School of Medicine, Northwestern University, Chicago, IL, USA
    Clin Genet 71:205-11. 2007
    ..This study shows that significant improvements in symptoms of skeletal disease are achievable clinical outcomes and treatment goals in GD type 1...
  74. ncbi The genetic basis for skeletal diseases
    Elazar Zelzer
    Harvard Medical School, Department of Cell Biology, 240 Longwood Avenue, Boston, Massachusetts 02115, USA
    Nature 423:343-8. 2003
    ....
  75. ncbi Abeta-2M-amyloidosis and related bone diseases
    Junichiro James Kazama
    Division of Clinical Nephrology and Rheumatology, Niigata University Graduate School of Medical and Dental Sciences, 1 754 Asahimachi dori, Niigata, 951 8510, Japan
    J Bone Miner Metab 24:182-4. 2006
    ..The precise cell biological mechanism of this inflammatory change is unknown. Further studies are needed to establish specific treatments against this as yet unsolved problem with long-term dialysis therapy...
  76. ncbi Screening plasma aluminum levels in relation to aluminum bone disease among asymptomatic dialysis patients
    A T Kausz
    Division of Nephrology, University of Washington, Seattle, WA, USA
    Am J Kidney Dis 34:688-93. 1999
    ..7%, respectively. We conclude that although there is a correlation between high aluminum levels and ABD, a patient's plasma aluminum level does not predict well the presence of ABD in spite of a relatively high prevalence of disease...
  77. ncbi Does the phosphate binder lanthanum carbonate affect bone in rats with chronic renal failure?
    Geert J Behets
    Department of Nephrology Hypertension, University of Antwerp, Belgium
    J Am Soc Nephrol 15:2219-28. 2004
    ..There was no evidence that lanthanum had a direct toxic effect on osteoblasts...
  78. ncbi RANK/RANKL: regulators of immune responses and bone physiology
    Andreas Leibbrandt
    IMBA, Institute for Molecular Biotechnology of the Austrian Academy of Sciences, Vienna, Austria
    Ann N Y Acad Sci 1143:123-50. 2008
    ....
  79. ncbi The osteoclast: friend or foe?
    Deborah V Novack
    Department of Pathology and Immunology, Division of Bone and Mineral Diseases, Washington University School of Medicine, St Louis, MO 63110, USA
    Annu Rev Pathol 3:457-84. 2008
    ..In these diseases, osteoclast activity causes bone loss that leads to pain, deformity, and fracture. Thus, osteoclasts are critical for normal bone function, but their activity must be controlled...
  80. ncbi [Monoclonal antibody targeting RANKL as a therapy for cancer-induced bone diseases]
    William Dougall
    Amgen Inc Washington, Department of Cancer Biology, Seattle, WA, USA
    Clin Calcium 16:627- 35. 2006
    ..Larger trials are underway to investigate the effect of denosumab for the treatment of cancer-induced bone disease and other bone loss disorders...
  81. ncbi New therapeutic agents for the treatment of bone diseases
    Allan Lipton
    Milton S Hershey Medical Center, Pennsylvania State University, 500 University Drive, Hershey, Pennsylvania, PA 17033, USA
    Expert Opin Biol Ther 5:817-32. 2005
    ..have demonstrated important clinical benefits for patients with malignant bone disease, metabolic bone diseases, such as Paget's disease, and postmenopausal osteoporosis...
  82. ncbi Future anti-catabolic therapeutic targets in bone disease
    Brendan F Boyce
    Department of Pathology and Laboratory Medicine, University of Rochester Medical Center, 601 Elmwood Avenue, Box 626, Rochester, NY, 14642, USA
    Ann N Y Acad Sci 1068:447-57. 2006
    ....
  83. ncbi Pamidronate reduces skeletal morbidity in women with advanced breast cancer and lytic bone lesions: a randomized, placebo-controlled trial. Protocol 18 Aredia Breast Cancer Study Group
    R L Theriault
    Department of Breast Medical Oncology, University of Texas M D Anderson Cancer Center, Houston 77030, USA
    J Clin Oncol 17:846-54. 1999
    ..To assess whether pamidronate can reduce the frequency of skeletal morbidity in women with lytic bone metastases from breast cancer treated with hormone therapy...
  84. ncbi Subchondral defects in caprine femora augmented with in situ setting hydroxyapatite cement, polymethylmethacrylate, or autogenous bone graft: biomechanical and histomorphological analysis after two-years
    Robert D Welch
    Seay Center for Musculoskeletal Research, Texas Scottish Rite Hospital for Children, Dallas 75219, USA
    J Orthop Res 20:464-72. 2002
    ....
  85. ncbi Myeloma bone disease: pathogenetic mechanisms and clinical assessment
    Franco Silvestris
    Department of Internal Medicine and Clinical Oncology DIMO, University of Bari, P za Giulio Cesare, 11 70124 Bari, Italy
    Leuk Res 31:129-38. 2007
    ....
  86. pmc Rapamycin and the transcription factor C/EBPbeta as a switch in osteoclast differentiation: implications for lytic bone diseases
    Jeske J Smink
    Max Delbrueck Center for Molecular Medicine, Humboldt University Berlin, Institute of Biology, Berlin Brandenburg Center for Regenerative Therapies, Robert Roessle Strasse 10, Berlin, Germany
    J Mol Med (Berl) 88:227-33. 2010
    Lytic bone diseases and in particular osteoporosis are common age-related diseases characterized by enhanced bone fragility due to loss of bone density...
  87. ncbi [Possibilities of whole-body MRI for investigating musculoskeletal diseases]
    S Lenk
    Abteilung für diagnostische Radiologie, Klinikum der Eberhardt Karls Universität Tübingen
    Radiologe 44:844-53. 2004
    ..Muscle, joint and bone diseases are discussed in which the application of whole-body MRI may be of advantage...
  88. ncbi Wnt signaling and potential applications in bone diseases
    Georges Rawadi
    Galapagos, 102 Gustave Roussel, 93230 Romainville, France
    Curr Drug Targets 9:581-90. 2008
    ..The existence of many potential pharmacological targets in this pathway makes it attractive for bone anabolic drug discovery...
  89. pmc Vitamin D in childhood and adolescence
    Kevin D Cashman
    Department of Food and Nutritional Sciences, Department of Medicine, University College, Cork, Ireland
    Postgrad Med J 83:230-5. 2007
    ..Therefore, consideration of potential corrective strategies to allow children and adolescents to maintain adequate vitamin D status throughout the year, even in the absence of adequate summer sun exposure, is warranted...
  90. ncbi Idiopathic calvarial thinning
    Satoshi Tsutsumi
    Department of Neurological Surgery, Juntendo University Urayasu Hospital, Urayasu, Chiba, Japan
    Neurol Med Chir (Tokyo) 48:275-8. 2008
    ..There was no markedly fibrovascular connective tissue typical of Gorham-Stout disease. Calvarial thinning in the present case may have been caused by an undetermined complex mechanism...
  91. ncbi Cytokines, osteoprotegerin, and RANKL in vitro and histomorphometric indices of bone turnover in patients with different bone diseases
    Heide Siggelkow
    Department for Gastroenterology and Endocrinology, University Clinic of Göttingen, Gottingen, Germany
    J Bone Miner Res 18:529-38. 2003
    ..TNF-alpha seemed to be the more important cytokine; its effect on bone resorption could be mediated by RANKL...
  92. ncbi [Bone substitutes]
    S M Schnürer
    Abteilung Orthopädie I, Stiftung Orthopädische Universitätsklinik Heidelberg
    Orthopade 32:2-10. 2003
    ....
  93. ncbi Bone-targeted 2,6,9-trisubstituted purines: novel inhibitors of Src tyrosine kinase for the treatment of bone diseases
    Yihan Wang
    ARIAD Pharmaceuticals, Inc, 26 Landsdowne Street, Cambridge, MA 02139 4234, USA
    Bioorg Med Chem Lett 13:3067-70. 2003
    ..A variety of bone-targeting groups with different affinity to hydroxyapatite were utilized in the study. Compound 3d was determined to be a potent Src inhibitor and was quite selective against a panel of other protein kinases...
  94. ncbi Novel bromomelatonin derivatives as potentially effective drugs to treat bone diseases
    Nobuo Suzuki
    Noto Marine Laboratory, Institute of Nature and Environmental Technology, Kanazawa University, Housu gun, Ishikawa, Japan
    J Pineal Res 45:229-34. 2008
    ..These studies identified a melatonin derivative that may have potential use in the treatment of bone diseases, such as osteoporosis.
  95. ncbi 'Magic bullets' for bone diseases: progress in rational design of bone-seeking medicinal agents
    Sufeng Zhang
    Department of Chemical and Materials Engineering, Faculty of Engineering, University of Alberta, Edmonton, Alberta, Canada T6G 2G6
    Chem Soc Rev 36:507-31. 2007
    An ideal therapeutic agent for bone diseases should act solely on bone tissue with no pharmacological activity at other anatomical sites...
  96. ncbi Myeloma bone disease
    Orhan Sezer
    Department of Hematology and Oncology, University Hospital Charite, Berlin, Germany
    Hematology 10:19-24. 2005
    ....
  97. ncbi Prevalence and risk factors of bone spavin in Icelandic horses in Sweden: a radiographic field study
    P Eksell
    Department of Clinical Radiology, Faculty of Veterinary Medicine, University of Agricultural Sciences, Uppsala, Sweden
    Acta Vet Scand 39:339-48. 1998
    ..Age when saddle broken in combination with height at the withers also influenced the multivariate logistic regression model significantly...
  98. ncbi Diagnostic value of magnetic resonance imaging of the forefeet in early rheumatoid arthritis when findings on imaging of the metacarpophalangeal joints of the hands remain normal
    Benedikt Ostendorf
    Heinrich Heine University of Duesseldorf, Duesseldorf, Germany
    Arthritis Rheum 50:2094-102. 2004
    ....
  99. ncbi Cellular and molecular interactions between immune system and bone
    D Grcevic
    Department of Physiology, Zagreb University School of Medicine, Salata 3b, 10000 Zagreb, Croatia
    Croat Med J 42:384-92. 2001
    ..The cytokines produced by immune cells may affect bone cell function and vice versa, but the full complexity of these interactions awaits further investigation...
  100. ncbi [Osteoarticular manifestations of Gaucher disease in adults: pathophysiology and treatment]
    E Hachulla
    Service de Medecine Interne, Hopital Claude Huriez, Centre National de Référence Maladies Métaboliques Rares de l enfant et de l adulte coordonné par le Dr D Dobbelaere, 59037 Lille, France
    Rev Med Interne 28:S180-2. 2007
  101. ncbi Clinical software for the assessment of trabecular bone disease in distal radius based on a magnetic resonance structural analysis
    Angel Alberich-Bayarri
    Biomedical Synergy, Universitat Politècnica de València, 46730 Gandia, Valencia, Spain
    Conf Proc IEEE Eng Med Biol Soc 2007:2073-6. 2007
    As Bone Mineral Density has been demonstrated to be insufficient to elaborate a correct diagnosis of bone diseases such as osteoporosis, a new software tool called EsTra has been developed in order to estimate the most significant ..

Research Grants70

  1. Immune Regulation of Bone Homeostasis
    MERVYN NEALE WEITZMANN; Fiscal Year: 2012
    ..basal bone turnover in young and aged individuals is central to our understanding of the pathophysiology of bone diseases and to the design of new effective countermeasures...
  2. Phosphorylation of FGF23 coordinates crosstalk between the skeleton and kidney
    VINCENT SCOTT TAGLIABRACCI; Fiscal Year: 2013
    ..In addition, collaborations were established with Kenneth White, PhD, a leader in the field of metabolic bone diseases and Joachim H. Ix, MD, a noted nephrologist and epidemiologist...
  3. Bisphosphonates in the treatment of chronic kidney disease-mineral bone disease
    Sharon M Moe; Fiscal Year: 2013
    ..Bisphosphonates are effective in preventing fractures in multiple non-CKD bone diseases, and can also improve arterial calcification in animal models...
  4. Osteoclastic Protein-Tyrosine Phosphatase and Resorption
    Kin Hing William Lau; Fiscal Year: 2013
    ..PUBLIC HEALTH RELEVANCE: Bone diseases, including osteoporosis and related bone-wasting diseases, are common in the VA patient population...
  5. Controlled delivery of polypeptide hormone calcitonin
    Jagdish Singh; Fiscal Year: 2013
    ..Development of such a novel therapeutic system is critical for successful treatment of bone diseases, especially osteoporosis in men and postmenopausal women, in order to improve patient quality of life.
  6. Conditional Knockout of Calcium Receptors in Bone Cells
    Dolores M Shoback; Fiscal Year: 2013
    ..calcium is doing in bone cells by removing calcium-sensing receptors selectively from the different types of cells in bone in a mouse model, to better understand bone metabolism and bone diseases, and to find more effective treatments.
  7. Assessment of Bone Composition Through a Novel Liquid/Solid State MRI Method
    Ara Nazarian; Fiscal Year: 2013
    ..To that end, we hypothesize that liquid+solid state MR imaging can be used to: differentiate metabolic bone diseases on the basis of bone tissue mineral composition and structural properties;and estimate the load capacity of ..
  8. Assessment of Bone Composition Through a Novel Liquid/Solid State MRI Method
    Ara Nazarian; Fiscal Year: 2011
    ..To that end, we hypothesize that liquid+solid state MR imaging can be used to: differentiate metabolic bone diseases on the basis of bone tissue mineral composition and structural properties;and estimate the load capacity of ..
  9. Roles of Gs Alpha and interaction with Wnt signaling in regulation of adipocyte d
    Partha S Sinha; Fiscal Year: 2011
    ..into adipocytes and osteoblasts may carry implications for metabolic diseases such as obesity and of bone diseases such as osteoporosis...
  10. ATF4 and Osteoclastogenesis
    Guozhi Xiao; Fiscal Year: 2013
    ..Abnormal OCL number and/or activity result in a number of bone diseases such as osteoporosis, Paget's disease of bone, metastatic osteolytic lesions, and rheumatoid arthritis...
  11. The role of IFT80 in bone formation
    Shuying Yang; Fiscal Year: 2013
    ..The long term objective of this work is to understand the functionmechanism and interactions of IFT/cilia proteins in bone development and bone diseases.
  12. Bc12 regulates osteoclast survival
    Junro Yamashita; Fiscal Year: 2010
    ..Hence, suppression of osteoclasts is a therapeutic strategy for the prevention and treatment of degenerative bone diseases. We have found, in preliminary studies, that homozygous mutant mice for B-cell leukemia/lymphoma 2 (Bcl2-/-) ..
  13. Non-Classical Manifestations of Primary Hyperparathyroidism
    Shonni J Silverberg; Fiscal Year: 2013
    ..cardiology fellow Iwata), enhancing my potential to add interdisciplinary perspectives to POR in metabolic bone diseases that should enhance our field...
  14. EBP50 Regulation of PTH Receptor in Bone
    Peter A Friedman; Fiscal Year: 2013
    ..will help define potential therapeutic targets for improved treatment of osteoporosis and other metabolic bone diseases. PUBLIC HEALTH RELEVANCE: The proposed studies will test how the adapter protein EBP50 regulates parathyroid ..
  15. Structural Basis for Synergistic Gene Expression by Runx1 and Ets1 Proteins
    Tahir H Tahirov; Fiscal Year: 2012
    ..cellular function and altered disease-related function contributing to cancer, in particular leukemias, and bone diseases, will help to develop novel, structure-based therapies to fight these diseases...
  16. Secretory Vesicle Function During Spermatogenesis & Fertilization in C. elegans
    STEVEN W L apos HERNAULT; Fiscal Year: 2010
    ..during spermatogenesis, V-ATPase function is defective in diseases that include renal Fanconi syndrome and the bone diseases, infantile ostepetrosis and osteoporosis...
  17. Understanding Wnt signaling through Ror and Ryk family receptor tyrosine kinases
    Mark A Lemmon; Fiscal Year: 2013
    ..unexpectedly, therefore, aberrations in Wnt signaling are now known to be involved in many diseases, including bone diseases, cancers, diabetes, neurodevelopment disorders, and several congenital malformations...
  18. The use of patient-specific iPS cells to identify osteoclast defects in CMD
    I Ping Chen; Fiscal Year: 2011
    DESCRIPTION (provided by applicant): More than 300 rare genetic bone diseases have been identified but treatment for these disorders is usually limited because little of their pathogeneses is known...
  19. FGF SIGNALING IN SKELETAL DEVELOPMENT, HOMEOSTASIS AND AGING
    David M Ornitz; Fiscal Year: 2013
    DESCRIPTION (provided by applicant): Osteoporosis and related bone diseases affect over 10 million Americans and result in 1.5 million fractures annually at a cost of $17-20 billion...
  20. The Aging Kidney in HIV-Infection: biomarkers for early detection of injury
    Michael G Shlipak; Fiscal Year: 2013
    ..persons are at greater risk of accelerated aging complications, including premature kidney, heart, and bone diseases. In the presence of HIV infection, the effect of aging on the kidney appears to be accelerated by 1-2 decades...
  21. INTERPLAYS BETWEEN THE JAW MESENCHYMAL STEM CELLS AND T LYMPHOCYTES
    Yufang Shi; Fiscal Year: 2010
    ..orofacial mesenchymal stem cells and immune cells and delineate the mechanisms by which the crosstalk may associate with orofacial bone diseases. We will use this knowledge to explore new approaches for orofacial bone disease treatment.
  22. Vitamin D and Clinical Outcomes in Chronic Hemodialysis Patients
    MICHEL BENJAMIN CHONCHOL; Fiscal Year: 2012
    ..Although vitamin D deficiency has long been known to cause bone diseases, evidence is rapidly accumulating in the general U.S...
  23. Transcriptional Regulation of Osteoclast Lineage Commitment and Differentiation
    Yi Ping Li; Fiscal Year: 2013
    ..by applicant): The long term goal of this study is to define new therapeutic targets of osteoclast related bone diseases, such as osteoporosis and tumor bone metastasis...
  24. Genetic Control of Osteoblast Differentiation
    Benoit de Crombrugghe; Fiscal Year: 2012
    ..bone formation is controlled, is of critical importance for identifying targets for appropriate therapies for bone diseases. Osterix is a transcription factor that is completely required for bone formation during embryonic development...
  25. TRAINING PROGRAM IN ENDOCRINOLOGY AND METABOLISM
    John P Bilezikian; Fiscal Year: 2013
    ..span a wide range of endocrinological disciplines with centers of excellence in neuroendocrinology, metabolic bone diseases, diabetes, reproductive endocrinology, endocrine genetics, lipoprotein metabolism, molecular endocrinology, ..
  26. Molecular Control of MSC differentiation and Bone Formation by KDM4B
    Cun Yu Wang; Fiscal Year: 2013
    ..modifiable, KDM4B may present as a novel therapeutic target for specifically controlling the differentiation of MSCs in regenerative medicine, and also lead to clues for new treatment in metabolic bone diseases such as, osteoporosis.
  27. DYNAMICS OF ASSEMBLY OF BONE MATRIX PROTEINS
    Sarah L Dallas; Fiscal Year: 2013
    ..and have key implications for skeletal diseases such as osteoporosis, arthritis, osteogenesis imperfecta and bone diseases related to ECM proteins...
  28. Function of Phospholipase Cgamma2 in RANKL-Induced Osteoclastogenesis
    Yabing Chen; Fiscal Year: 2010
    ..osteoclastogenesis and may lead to develop novel strategies and targets to prevent and cure osteolytic-based bone diseases. Pathogenic bone resorption modulated by elevation of osteoclasts is a major cause of bone loss related ..
  29. Novel Mechanism of PTH Effects on Bone Metabolism
    Bin Wang; Fiscal Year: 2013
    ..studies will not only contribute to understanding the mechanisms of PTH treatment of osteoporosis, but also provide important insight into designing pharmacological agents for treatment of metabolic bone diseases such as osteoporosis.
  30. The Mechanism of Excess Neural Crest-Derived Craniofacial Bone Formation in a Mou
    Fei Liu; Fiscal Year: 2012
    ..acquisition signals, which are fundamentally important for the development of new therapeutics to treat other bone diseases such as osteoporosis...
  31. Molecular and Cellular Pathogenesis of Cherubism
    Yasuyoshi Ueki; Fiscal Year: 2013
    ..mice are useful, not only as a model of cherubism, but also potentially as a model for other inflammatory bone diseases. The overall hypothesis for the proposed studies is that the misexpression and disregulation of TNF-1 in ..
  32. Innate Immune Bacterial Recognition and Osteoclastogenesis
    Caroline A Genco; Fiscal Year: 2010
    ..In other inflammatory bone diseases these cells have been reported to contribute to the acceleration of bone resorption by the production of ..
  33. Regulatory mechanisms in osteoclasts
    Yongwon Choi; Fiscal Year: 2013
    ..lead to novel or improved therapeutic strategies for the treatment and prevention of osteoporosis and other bone diseases. PUBLIC HEALTH RELEVANCE: Osteoclasts are the principal, if not the only, cells that can resorb bone...
  34. Targeting bone homing of the MSCs to augment bone formation
    Wei Yao; Fiscal Year: 2010
    ..The major obstacle for MSCs therapeutic application in bone diseases is that MSCs do not home to bone...
  35. Fourth International MHE Research Conference
    Maurizio Pacifici; Fiscal Year: 2012
    ..human genetics, developmental biology, heparan sulfate chemistry, animal disease models and related bone diseases, and about 50 participants (including over 3o invited speakers and non-speaking discussants)...
  36. Roles of Smad1 Dephosphorylation in Osteoblast Differentiation
    Xin Hua Feng; Fiscal Year: 2012
    ..to Bone Morphogenetic Proteins (BMPs) and other members of TGF-( superfamily are associated with human bone diseases such as osteoporosis, pulmonary hypertension and heritable cancer...
  37. Next generation bisphosphonates for chemo- and immuno-therapy
    Eric Oldfield; Fiscal Year: 2013
    ..design other anti-cancer drugs that bind to bone, realizing the long sought after goal of "magic bullets" for bone diseases. In Aim 1, we will develop compounds that inhibit two prenyl synthase enzymes: farnesyl diphosphate synthase (..
  38. The use of patient-specific iPS cells to identify osteoclast defects in CMD
    I Ping Chen; Fiscal Year: 2013
    Project Summary/Abstract More than 300 rare genetic bone diseases have been identified but treatment for these disorders is usually limited because little of their pathogeneses is known...
  39. Optimizing Osteotropism of Human Mesenchymal Stem Cells
    Robert Sackstein; Fiscal Year: 2010
    ..g., heart), direct insertion is impractical for systemic conditions such as generalized bone diseases (e.g., Osteogenesis Imperfecta)...
  40. Computational Biomechanics for Prediction of Osteoporotic Vertebral Fracture Risk
    Chamith Sudesh Rajapakse; Fiscal Year: 2013
    ..Felix W. Wehrli, Ph.D.), endocrinological aspects of metabolic bone diseases (Prof. Peter J. Snyder, M.D.), and image-based biomechanical modeling and mechanical testing (Prof. X...
  41. Role of Macrophage Migration Inhibitory Factor in Osteoclastogenesis
    Sun Kyeong Lee; Fiscal Year: 2013
    ..new target for interventions, which can be used to create therapies to reverse bone loss, improve bone quality and prevent the morbidities that are associated with the development of osteoporosis and other metabolic bone diseases.
  42. IGF::OT::IGF SUPPORT SERVICES FOR TWO INFORMATION CLEARINGHOUSES, NIAMS, NIH
    Kim Holmes; Fiscal Year: 2013
    ..and the media through the NIAMS Information Clearinghouse (NIC) and the NIH Osteoporosis and Related Bone Diseases~National Resource Center (NRC) and under the direction of the NIAMS Office of Communications and Public ..
  43. Support Services for Two National Information Clearinghouses
    KIMBERLY HOLMES; Fiscal Year: 2011
    ..and the media through the NIAMS Information Clearinghouse (NIC) and the NIH Osteoporosis and Related Bone Diseases~National Resource Center (NRC) and under the direction of the NIAMS Office of Communications and Public ..
  44. Support Services for Two National Information Clearinghouses
    JENNIFER BLACKER; Fiscal Year: 2010
    ..and the media through the NIAMS Information Clearinghouse (NIC) and the NIH Osteoporosis and Related Bone Diseases~National Resource Center (NRC) and under the direction of the NIAMS Office of Communications and Public ..
  45. Support Services for Two National Information Clearinghouses
    KIMBERLY HOLMES; Fiscal Year: 2012
    ..and the media through the NIAMS Information Clearinghouse (NIC) and the NIH Osteoporosis and Related Bone Diseases~National Resource Center (NRC) and under the direction of the NIAMS Office of Communications and Public ..
  46. UAB Core Center for Basic Skeletal Research (CCBSR)
    Selvarangan Ponnazhagan; Fiscal Year: 2010
    ..Core have proven essential to the stimulation of innovative research targeting complex, multifactorial bone diseases, and have led to the rapid formation of new collaborative efforts as the research unfolds...
  47. DYNAMICS OF ASSEMBLY OF BONE MATRIX PROTEINS
    SARAH DALLAS; Fiscal Year: 2009
    ..of the molecular and dynamic mechanisms underlying bone formation and have key implications for skeletal diseases such as osteoporosis, arthritis, osteogenesis imperfecta and bone diseases related to ECM proteins.
  48. Mechanisms and function of the microtubule podosome connection in osteoclasts
    ROLAND E BARON; Fiscal Year: 2013
    DESCRIPTION (provided by applicant): Increased osteoclastic resorption is responsible for multiple bone diseases, whether systemic (osteoporosis, Paget's disease, hyper-parathyroidism for instance) or local (rheumatoid arthritis, ..
  49. Request for VivaCT 75 High Speed in vivo MicroCT Scanner
    Jie Song; Fiscal Year: 2010
    ..repair, and addressing novel therapeutic approaches for osteoarthritis, rheumatoid arthritis, and metastatic bone diseases. These on-going studies can significantly benefit from the instrument's capability to carry out ..
  50. The Mechanism of Coupling Bone Resorption and Formation
    Xu Cao; Fiscal Year: 2010
    ..Ultimately, this study will lead to reveal a mechanism of coupling bone resorption and formation and improve the treatment for bone diseases with coupling disorder.
  51. Integral role of hematopoietic cells in PTH actions in bone
    Laurie McCauley; Fiscal Year: 2009
    ..This information is critical for the optimization of PTH as a therapy for bone regeneration and the treatment of bone diseases such as periodontal disease and osteoporosis.
  52. RANK Signaling in Osteoclast Differentiation and Function
    Xu Feng; Fiscal Year: 2013
    ..is to fully delineate RANK signaling in OC biology with an aim of identifying novel therapeutic targets for bone diseases. As a member of the TNF receptor (TNFR) family, RANK activates various signaling pathways including NF-?B, JNK,..
  53. Regulation of Bone Formation by G-protein Signaling
    Edward C Hsiao; Fiscal Year: 2013
    ..elucidating the mechanisms that regulate bone formation is crucial for understanding the pathologic changes in bone diseases and for developing targeted treatments to increase bone formation...
  54. Cadherin Mediated Cell-Cell Interactions in the Bone Microenvironment
    Roberto Civitelli; Fiscal Year: 2013
    Defective bone remodeling is the pathophysiologic basis of most metabolic bone diseases, including postmenopausal and age-dependent osteoporosis...
  55. STUDIES OF THE FATE OF THE OSTEOCLAST
    Brendan F Boyce; Fiscal Year: 2013
    ..by applicant): Osteoclasts are essential for bone modeling and remodeling and mediate bone loss in common bone diseases, including rheumatoid arthritis and postmenopausal osteoporosis, in which levels of proinflammatory cytokines, ..
  56. Molecular basis of mechanotransduction in bone cells
    Jun You; Fiscal Year: 2013
    ..Completion of this project will ultimately lead to novel targets for pharmacological intervention in bone diseases that have a mechanical component, such as osteoporosis.
  57. Heparan Sulfate in Skeletal Development and Diseases
    Yu Yamaguchi; Fiscal Year: 2012
    ..by the existence of the genetic (hereditary multiple exostosis) and metabolic (heparin- induced osteoporosis) bone diseases that are directly linked to aberrant expression of heparan sulfate...
  58. Lrp5-dependent regulation of bone mass accrual by gut-derived serotonin
    Gerard Karsenty; Fiscal Year: 2013
    ..Based on this body of preliminary data we hypothesize that, in mice and men, the bone diseases triggered by loss- or gain-of-function mutations in Lrp5 are endocrine diseases originating from the gut and ..
  59. PRIMARY HYPERPARATHYROIDISM
    John P Bilezikian; Fiscal Year: 2012
    ..hyperparathyroidism, a disorder of excess parathyroid hormone secretion, is one of the most common metabolic bone diseases. The project is designed to elucidate aspects of this disorder that have been elusive, but which when ..
  60. Bone-seeking and cell-targeting non-viral vectors for BMP-2 gene delivery
    Chuanbin Mao; Fiscal Year: 2011
    ..Such vectors can be used for the repair and regeneration of musculoskeletal tissues and treatment of genetic based bone diseases such as osteogenesis imperfecta by gene therapy.
  61. Embryonic stem cell-derived osteoprogenitor cells for bone formation and repair
    Ross A Kopher; Fiscal Year: 2010
    DESCRIPTION (provided by applicant): Novel therapeutic approaches to treat bone diseases remain a critical medical issue...
  62. Hybrid Organic-Inorganic Composite Materials for Bone Repairs
    ADEREMI R OKI; Fiscal Year: 2012
    ..involves the fabrication of synthetic composite materials that can be utilized in bone repair or treatment of bone diseases. These lightweight composites are biocompatible and are able to stimulate bone mineral formation in body fluid. ..
  63. SERUM OSTEOCLASTIC ACID PHOSPHATASE IMMUNOASSAY
    KIN HING LAU; Fiscal Year: 1993
    ..resorption is needed for rapid diagnoses and close monitoring of the effectiveness of treatments of metabolic bone diseases. Currently no such blood or urine test is generally available...
  64. BONE RESPONSE TO COMBINED MECHANICAL AND PTH STIMULATION
    X Guo; Fiscal Year: 2005
    Trabecular bone adaptation plays a significant role in the etiology of many metabolic bone diseases such as osteoporosis and osteopetrosis, bone loss in microgravity, and the long term success or failure of porous implants in total ..
  65. Mechanotransduction in Osteocytic Network and Osteoblast
    X Guo; Fiscal Year: 2007
    ..and failure of normal bone adaptation is known to play a significant role in the etiology of metabolic bone diseases such as osteoporosis and osteopetrosis, bone loss in space flight, and in the failure of total joint ..
  66. REGULATION OF BONE RESORPTION
    Julie Glowacki; Fiscal Year: 1991
    ..of bone resorption by hormones and drugs could provide a rational basis for the treatment of metabolic bone diseases involving increased bone resorption (e.g. osteoporosis and Paget's disease) and of inflammatory bone lysis (e...
  67. Bisphosphonate binding to connexin43-expressing cells
    Teresita Bellido; Fiscal Year: 2007
    ..The PI of the application is Dr. Teresita Bellido from the Center of Osteoporosis and Metabolic Bone Diseases of the University of Arkansas for Medical Sciences, USA. The foreign collaborator is Dr...
  68. Sun Valley Workshop on Skeletal Biology
    David Burr; Fiscal Year: 2009
    ..to discuss the pathogenesis and treatment of osteoporosis, osteoarthrosis, and muscle sarcopenia and metabolic bone diseases associated with regulation of energy metabolism and fat in the skeleton...
  69. Liquid Chromatography Tandem Mass Spectrometry
    Christina Wang; Fiscal Year: 2009
    ..These investigators are engaged in a wide spectrum of research spanning from metabolic bone diseases inflicting children and the elderly, hormonal deficiencies in men and women, hormone and non-hormone dependent ..
  70. LIF/IL6 INDUCED SIGNAL TRANSDUCTION IN BONE CELLS
    Mark Horowitz; Fiscal Year: 1999
    ..bone cells, these factors have been implicated in the regulation of normal bone remodeling and the etiology of bone diseases like osteoporosis...